SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021
Open accessAbstract
COVID-19 vaccines fully approved or currently authorized for use through Emergency Use Authorization from the Food and Drug Administration are critical tools for controlling the COVID-19 pandemic; however, even with highly effective vaccines, a proportion of fully vaccinated persons will become infected with SARS-CoV-2, the virus that causes COVID-19 (1). To characterize postvaccination infections, the Los Angeles County Department of Public Health (LACDPH) used COVID-19 surveillance and California Immunization Registry 2 (CAIR2) data to describe age-adjusted infection and hospitalization rates during May 1-July 25, 2021, by vaccination status. Whole genome sequencing (WGS)-based SARS-CoV-2 lineages and cycle threshold (Ct) values from qualitative reverse transcription-polymerase chain reaction (RT-PCR) for two SARS-CoV-2 gene targets, including the nucleocapsid (N) protein gene region and the open reading frame 1 ab (ORF1ab) polyprotein gene region,* were reported for a convenience sample of specimens. Among 43,127 reported SARS-CoV-2 infections in Los Angeles County residents aged ≥16 years, 10,895 (25.3%) were in fully vaccinated persons, 1,431 (3.3%) were in partially vaccinated persons, and 30,801 (71.4%) were in unvaccinated persons. Much lower percentages of fully vaccinated persons infected with SARS-CoV-2 were hospitalized (3.2%), were admitted to an intensive care unit (0.5%), and required mechanical ventilation (0.2%) compared with partially vaccinated persons (6.2%, 1.0%, and 0.3%, respectively) and unvaccinated persons (7.6%, 1.5%, and 0.5%, respectively) (p<0.001 for all comparisons). On July 25, the SARS-CoV-2 infection rate among unvaccinated persons was 4.9 times and the hospitalization rate was 29.2 times the rates among fully vaccinated persons. During May 1-July 25, the percentages of B.1.617.2 (Delta) variant infections estimated from 6,752 samples with lineage data increased among fully vaccinated persons (from 8.6% to 91.2%), partially vaccinated persons (from 0% to 88.1%), and unvaccinated persons (from 8.2% to 87.1%). In May, there were differences in median Ct values by vaccination status; however, by July, no differences were detected among specimens from fully vaccinated, partially vaccinated, and unvaccinated persons by gene targets. These infection and hospitalization rate data indicate that authorized vaccines were protective against SARS-CoV-2 infection and severe COVID-19 during a period when transmission of the Delta variant was increasing. Efforts to increase COVID-19 vaccination, in coordination with other prevention strategies, are critical to preventing COVID-19-related hospitalizations and deaths.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
With very low efficacy in the COVID-19 vaccines, alternative factors could explain high rates of hospitalized COVID-19 cases in unvaccinated people.
“Additionally, with very low efficacy in the COVID-19 vaccines, alternative factors could explain high rates of hospitalized COVID-19 cases in unvaccinated people [30].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [30]
The Discussion states that authorized vaccines protect against SARS-CoV-2 infection and severe COVID-19, contrary to the claim of very low efficacy. The report also finds that, on July 25, the age-adjusted hospitalization rate was 29.2 times higher among unvaccinated than fully vaccinated persons. Its limitations note possible incidental hospitalizations but do not present alternative factors as an explanation for that difference. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredOne consequence of misinforming the public that the COVID-19 mRNA vaccine efficacy is very high is the expectation that the vaccines will protect people from severe infections, hospitalizations, and death.
“One of the consequences of misinforming the public that the COVID-19 mRNA vaccine efficacy is very high is the expectation that the vaccines will protect people from severe infections, hospitalizations, and death [30].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [30]
The Discussion states that authorized vaccines protect against severe COVID-19 and that vaccinated people with infections were less likely to be hospitalized or die. The paper also calls the vaccines highly effective, but it does not describe that message as misinformation or study whether it created public expectations. (LLM, conf=0.87)
Experimental — accuracy not yet measuredVaccine-induced immunity remains effective at preventing severe disease, hospitalization, and death even at later time points when antibody levels may have declined.
“Yet, vaccine-induced immunity remains effective at preventing severe disease, hospitalization, and death, even at later time points when antibody levels may have declined (10–12).”
From mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern (2021) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889 · see citing works
Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939 · see citing works
Brown, C., Vostok, J., Johnson, H., Burns, M., Gharpure, R. V., Sami, S., Sabo, R. T., Hall, N. B., Foreman, A., Schubert, P. L., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7031e2 · Cited by 491 · see citing works
COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021
CDC COVID-19 Vaccine Breakthrough Case Investigations Team, CDC COVID-19 Vaccine Breakthrough Case Investigations Team, Birhane, M., Bressler, S., Chang, G., Clark, T., Dorough, L., Fischer, M., Watkins, L. F., Goldstein, J. M., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7021e3 · Cited by 421 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [3]Allen H, Vusirikala A, Flannagan J,; Public Health England. Increased household transmission of COVID-19 cases associated with SARS-CoV-2 variant of concern B.1.617.2: a national case-control study. Knowledge Hub [Preprint posted online June 18, 2021]. https://khub.net/documents/135939561/405676950/Increased+Household+Transmission+of+COVID-19+Cases+-+national+case+study.pdf/7f7764fb-ecb0-da31-77b3-b1a8ef7be9aa
- [5]Nasreen S, He S, Chung H, Effectiveness of COVID-19 vaccines against variants of concern, Canada [ Preprint posted online July 16, 2021]. https://www.medrxiv.org/content/10.1101/2021.06.28.21259420v2 · DOI
Cited by
Sorted by citations
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
Goel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., et al. (2021) · Science · doi:10.1126/science.abm0829 · Cited by 873 · see citing works
Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy
Brown, R. B. (2022) · Dialogues in Health · doi:10.1016/j.dialog.2022.100074 · Cited by 11 · see citing works
- Authors
- Griffin, J. B., Haddix, M., Danza, P., Fisher, R., Koo, T. H., Traub, E., Gounder, P., Jarashow, C., & Balter, S.
- Affiliations
- Los Angeles County Department of Public Health (US)
- Corresponding author
- Griffin, Jennifer B.
- Venue
- MMWR. Morbidity and Mortality Weekly Report
- Published
- 2021-08-27
- Volume
- 70
- Issue
- 34
- Pages
- 1170-1176
- ISSN
- 0149-2195 (ISSN-L)
- 1545-861X
- PMC
- PMC8389389
- OpenAlex
- W3195533500
- Cited by
- 125
- References
- 4
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 8 · 2023: 21 · 2022: 66 · 2021: 24
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- MMWR Morbidity and Mortality Weekly Report (publishedVersion)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- SARS-CoV-2, COVID-19 pandemic, COVID-19 vaccination, breakthrough infection, hospitalization, intensive care unit admission, mechanical ventilation, SARS-CoV-2 lineages, Delta variant, Omicron variant, vaccination status, Los Angeles County, whole genome sequencing
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Adolescent, Adult, Aged, Female, Hospitalization, Humans, Male, Middle Aged, Vaccination, Los Angeles, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review